Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters











Publication year range
1.
Mov Disord ; 26(9): 1677-83, 2011 Aug 01.
Article in English | MEDLINE | ID: mdl-21638322

ABSTRACT

Consistent with the hypothesis that dopamine is implicated in the processing of salient stimuli relevant to the modification of various behavioral responses, Parkinson's disease is associated with emotional blunting. To address the hypothesis that emotional attention and memory are modulated by dopaminergic neurotransmission in Parkinson's disease, we assessed 15 nondemented patients with Parkinson's disease while on and off dopaminergic medication and 15 age-matched healthy controls. Visual stimuli were presented, and recognition was used to assess emotional memory. Response latency was used as a measure of emotional attention modulation. Stimuli were varied based on valence (pleasant, neutral, and unpleasant) and arousal (high and low) dimensions. Controls had significantly better memory for positive than negative stimuli, whereas patients with Parkinson's disease tested off medication had significantly better memory for negative than positive items. This negativity bias was lost when they were tested while on dopaminergic medication. Reaction times in patients with Parkinson's disease off medication were longer than in healthy controls and, paradoxically, were even longer when on medication. Further, although both healthy controls and patients with Parkinson's disease in the "off" state had arousal-induced prolongation of reaction time, this effect was not seen in patients with Parkinson's disease on medication. These data indicate that dopaminergic neurotransmission is implicated in emotional memory and attention and suggest that dopamine mediates emotional memory via the valence dimension and emotional attention via arousal. Furthermore, our findings suggest that emotional changes in Parkinson's disease result from the effects of both the disease process and dopaminergic treatment.


Subject(s)
Attention/drug effects , Dopamine Agents/pharmacology , Emotions/drug effects , Parkinson Disease/physiopathology , Recognition, Psychology/drug effects , Aged , Analysis of Variance , Case-Control Studies , Dopamine Agents/therapeutic use , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Parkinson Disease/drug therapy , Photic Stimulation/methods , Reaction Time
2.
Int J Neurosci ; 121(8): 430-6, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21574890

ABSTRACT

Whereas aging affects cognitive and psychomotor processes negatively, the impact of aging on emotional processing is less clear. Using an "old-new" binary decision task, we ascertained the modulation of response latencies after presentation of neutral and emotional pictures in "young" (M = 27.1 years) and "young-old" adults with a mean age below 60 (M = 57.7 years). Stimuli varied on valence (pleasant, neutral, and unpleasant) and arousal (high and low) dimensions. Young-old adults had significantly longer reaction times. However, young and young-old adults showed the exact same pattern of response time modulation by emotional stimuli: Response latencies were longer for high-arousal than for low-arousal pictures and longer for negative than for positive or neutral stimuli. This result suggests that the specific effects of implicitly processed emotional valence and arousal information on behavioral response time are preserved in young-old adults despite significant age-related psychomotor decline.


Subject(s)
Aging/physiology , Arousal , Emotions/physiology , Reaction Time/physiology , Adult , Aged , Female , Humans , Male , Middle Aged , Photic Stimulation/methods , Young Adult
3.
J Neural Transm (Vienna) ; 118(9): 1319-22, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21519950

ABSTRACT

Emotions can affect various aspects of human behavior. The impact of emotions on behavior is traditionally thought to occur at central, cognitive and motor preparation stages. Using EMG to measure the effects of emotion on movement, we found that emotional stimuli differing in valence and arousal elicited highly specific effects on peripheral movement time. This result has conceptual implications for the emotion-motion link and potentially practical implications for neurorehabilitation and professional environments where fast motor reactions are critical.


Subject(s)
Emotions/physiology , Mental Processes/physiology , Movement/physiology , Psychomotor Performance/physiology , Reaction Time/physiology , Aged , Arousal/physiology , Electromyography/methods , Female , Humans , Male , Middle Aged , Photic Stimulation/methods
4.
Muscle Nerve ; 43(4): 537-42, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21305570

ABSTRACT

INTRODUCTION: Are there electrophysiological findings that predict response to intravenous immunoglobulin (IVIg) in patients with lower motor neuron (LMN) syndromes without multifocal conduction block (MCB)? METHODS: We enrolled 9 patients with LMN syndromes without MCB to receive 18 weeks of IVIg therapy. Response was measured at weeks 2 and 18 using the Appel Amyotrophic Lateral Sclerosis (AALS) score (includes grip and pincer strength measures), ALS Functional Rating Scale (ALSFRS), and electrophysiological measures, including motor unit estimates (MUNEs). RESULTS: No change occurred in AALS or ALSFRS scores posttreatment. Grip/pincer strength increased in 7 patients (P = 0.028) after initial treatment (responders); 2 showed no improvement (non-responders). No electrophysiological measure changed after treatment in either group but MUNEs trended higher (P = 0.055). "Abnormal A-waves" (complex, repetitive biphasic, or present in multiple nerves) occurred in pretreatment studies more often in responders (P = 0.028). DISCUSSION: "Abnormal A-waves" may signal IVIg-responsive LMN syndromes even if conduction block is absent.


Subject(s)
Immunoglobulins, Intravenous/administration & dosage , Muscle Strength/drug effects , Neural Conduction/drug effects , Polyneuropathies/drug therapy , Polyneuropathies/physiopathology , Adult , Female , Humans , Male , Middle Aged , Muscle Strength/physiology , Neural Conduction/physiology , Pilot Projects , Predictive Value of Tests , Treatment Outcome
5.
Clin Auton Res ; 19(6): 375-80, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19834645

ABSTRACT

OBJECTIVE: To determine whether the heart rate changes during tilt table testing could be used in the differential diagnosis between vasovagal syncope and chronic autonomic failure. METHODS: We compared the relationship between electrocardiographic R-R intervals and beat-to-beat blood pressure in 43 patients with typical vasovagal responses and 30 patients with chronic autonomic failure (6 pure autonomic failure, 23 multiple system atrophy, and 1 Parkinson's disease). RESULTS: In every patient with vasovagal syncope, at the time when the blood pressure was falling, it was possible to identify at least 12 successive heart beats (mean 33 +/- 2 heart beat, range 12-57) when blood pressure and heart rate fell in parallel, i.e., there was a negative relationship between blood pressure and R-R intervals (P < 0.001). In contrast, the relationship between blood pressure and R-R intervals in patients with chronic autonomic failure was never negative, i.e., heart rate always increased, albeit less than expected for the given fall in blood pressure, or remained unchanged. INTERPRETATION: The heart rate changes during the fall in blood pressure can distinguish patients with vasovagal responses from those with chronic autonomic failure.


Subject(s)
Autonomic Nervous System/physiopathology , Blood Pressure/physiology , Heart Rate/physiology , Pure Autonomic Failure/diagnosis , Syncope, Vasovagal/diagnosis , Adult , Chronic Disease , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Pure Autonomic Failure/physiopathology , Retrospective Studies , Syncope, Vasovagal/physiopathology , Tilt-Table Test
6.
Pediatr Res ; 65(3): 341-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19033881

ABSTRACT

Familial dysautonomia (FD) is caused by an intronic splice mutation in the IkappaB kinase-associated protein gene (IKBKAP) that leads to partial skipping of exon 20 and tissue-specific reduction of IkappaB kinase-associated protein/elongator protein 1 (IKAP/ELP-1 protein). Kinetin increases IKBKAP mRNA and protein expression in FD cell lines. To determine whether oral kinetin alters IKBKAP splicing in vivo, we administered kinetin to 29 healthy carriers of the major FD mutation for 8 d. Adverse effects, kinetin, and IKBKAP mRNA levels were monitored. In the highest dosing cohorts (23.5 mg/kg/d), the target plasma kinetin level was achieved in 91% of subjects at 2 h. After 8 d, IKBKAP mRNA expression in leukocytes increased as kinetin levels increased. There is a linear association between log plasma kinetin level and corresponding log change from baseline in IKBKAP mRNA expression that allows estimation of IKBKAP mRNA levels because of kinetin ingestion. Adverse effects were transient and mild. This is the first report of in vivo IKBKAP splicing modification and strongly suggests kinetin's therapeutic potential in FD and perhaps in other splicing disorders. Furthermore, our findings support our hypothesis that treatments, which target a particular splicing mutation, can be successfully developed.


Subject(s)
Alternative Splicing/genetics , Carrier Proteins/genetics , Dysautonomia, Familial/genetics , Gene Expression Regulation/drug effects , Heterozygote , Kinetin/pharmacology , RNA, Messenger/metabolism , Adult , Alternative Splicing/drug effects , Carrier Proteins/metabolism , Dose-Response Relationship, Drug , Dysautonomia, Familial/drug therapy , Female , Humans , Kinetin/blood , Kinetin/pharmacokinetics , Male , Mutation/genetics , RNA, Messenger/genetics , Statistics, Nonparametric , Transcriptional Elongation Factors
7.
Depress Anxiety ; 26(3): 251-8, 2009.
Article in English | MEDLINE | ID: mdl-18839407

ABSTRACT

BACKGROUND: Panic disorder (PD) patients have been shown to have reduced heart rate variability (HRV). Low HRV has been associated with elevated risk for cardiovascular disease. Our aim was to investigate the effects of treatment on heart rate (HR) in patients with PD through a hyperventilation challenge. METHODS: We studied 54 participants, 43 with Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) PD and 11 controls. Subjects lay supine with their heads in a plastic canopy chamber, resting for 15 min and then breathing at a rate of 30 breaths per minute for 10 min. HRV was sampled for spectral analysis. Clinical and behavioral measures of anxiety were assessed. Treatment was chosen by patients: either 12 weeks of CBT alone or CBT with sertraline. RESULTS: All patients showed significant decrease on clinical measures from baseline and 31 were treatment responders, 8 dropped out of the study before completion of the 12-week treatment phase and 4 were deemed nonresponders after 12 weeks of treatment. Although both treatments led to significant clinical improvement, only CBT alone demonstrated a significant reduction in HR and increase in HRV. CONCLUSIONS: Our study replicated the finding that increased HR and decreased HRV occur in PD patients. Given the evidence of cardiac risk related to HRV, CBT appears to have additional benefits beyond symptom reduction. The mechanisms of this difference between CBT and sertraline are unclear and require further study.


Subject(s)
Heart Rate/drug effects , Panic Disorder/therapy , Psychotherapy/methods , Sertraline/pharmacology , Sertraline/therapeutic use , Adolescent , Adult , Aged , Diagnostic and Statistical Manual of Mental Disorders , Drug Administration Schedule , Electrocardiography , Female , Humans , Life Change Events , Male , Middle Aged , Panic Disorder/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Sertraline/administration & dosage , Young Adult
8.
Muscle Nerve ; 37(5): 668-72, 2008 May.
Article in English | MEDLINE | ID: mdl-18288708

ABSTRACT

Progression of disease and effectiveness of therapy in patients with amyotrophic lateral sclerosis (ALS) are determined by both questionnaire- and examination-based measures. To determine whether both types of measurement tools are equally predictive at all stages of disease, we compared questionnaire-based ALS Functional Rating Scale (ALSFRS) scores to the examination-based Appel ALS (AALS) scores at different stages of disease. Same-day scores were obtained during 174 visits in 62 patients with definite or probable ALS. Using normalized scores, correlation between the scales and predictability were best in mildly affected patients. Predictions of ALSFRS based on AALS scores were less than half as precise in the later stages of disease. Both scales showed significant change with disease progression, but ALSFRS consistently underestimated disease severity defined by AALS (P < 0.001). Questionnaire-based measurements should be compared against objective scales at all stages of disease severity before they are accepted as primary endpoint measures.


Subject(s)
Amyotrophic Lateral Sclerosis/physiopathology , Severity of Illness Index , Surveys and Questionnaires , Adult , Aged , Aged, 80 and over , Analysis of Variance , Disease Progression , Female , Humans , Linear Models , Male , Middle Aged , Sickness Impact Profile
9.
BMC Neurosci ; 7: 29, 2006 Apr 03.
Article in English | MEDLINE | ID: mdl-16584562

ABSTRACT

BACKGROUND: The cause of neuronal death in amyotrophic lateral sclerosis (ALS) is uncertain but mitochondrial dysfunction may play an important role. Ketones promote mitochondrial energy production and membrane stabilization. RESULTS: SOD1-G93A transgenic ALS mice were fed a ketogenic diet (KD) based on known formulations for humans. Motor performance, longevity, and motor neuron counts were measured in treated and disease controls. Because mitochondrial dysfunction plays a central role in neuronal cell death in ALS, we also studied the effect that the principal ketone body, D-beta-3 hydroxybutyrate (DBH), has on mitochondrial ATP generation and neuroprotection. Blood ketones were > 3.5 times higher in KD fed animals compared to controls. KD fed mice lost 50% of baseline motor performance 25 days later than disease controls. KD animals weighed 4.6 g more than disease control animals at study endpoint; the interaction between diet and change in weight was significant (p = 0.047). In spinal cord sections obtained at the study endpoint, there were more motor neurons in KD fed animals (p = 0.030). DBH prevented rotenone mediated inhibition of mitochondrial complex I but not malonate inhibition of complex II. Rotenone neurotoxicity in SMI-32 immunopositive motor neurons was also inhibited by DBH. CONCLUSION: This is the first study showing that diet, specifically a KD, alters the progression of the clinical and biological manifestations of the G93A SOD1 transgenic mouse model of ALS. These effects may be due to the ability of ketone bodies to promote ATP synthesis and bypass inhibition of complex I in the mitochondrial respiratory chain.


Subject(s)
Amyotrophic Lateral Sclerosis/diet therapy , Amyotrophic Lateral Sclerosis/metabolism , Diet , Ketone Bodies/biosynthesis , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/physiopathology , Animals , Cell Survival/drug effects , Disease Progression , Hydroxybutyrate Dehydrogenase/pharmacology , Ketone Bodies/blood , Male , Mice , Mice, Transgenic , Mitochondria/drug effects , Motor Neurons/drug effects , Superoxide Dismutase/genetics
10.
Exp Brain Res ; 171(2): 251-61, 2006 May.
Article in English | MEDLINE | ID: mdl-16308690

ABSTRACT

Muscle sympathetic nerve activity (MSNA) is modulated on a beat-to-beat basis by the baroreflex. Vestibular input from the otolith organs also modulates MSNA, but characteristics of the vestibulo-sympathetic reflex (VSR) are largely unknown. The purpose of this study was to elicit the VSR with electrical stimulation to estimate its latency in generating MSNA. The vestibular nerves of seven subjects were stimulated across the mastoids with short trains of high frequency, constant current pulses. Pulse trains were delivered every fourth heartbeat at delays of 300-700 ms after the R wave of the electrocardiogram. Vestibular nerve stimulation given 500 ms after the R wave significantly increased baroreflex-driven MSNA, as well as the diastolic blood pressure threshold at which bursts of MSNA occurred. These changes were specific to beats in which vestibular stimulation was applied. Electrical stimulation across the shoulders provided a control condition. When trans-shoulder trials were subtracted from trials with vestibular nerve stimulation, eliminating the background baroreflex-driven sympathetic activity, there was a sharp increase in MSNA beginning 660 ms after the vestibular nerve stimulus and lasting for about 60 ms. The increase in the MSNA produced by vestibular nerve stimulation, and the associated increase in the diastolic blood pressure threshold at which the baroreflex-driven bursts occurred, provide evidence for the presence of a short-latency VSR in humans that is likely to be important for the maintenance of blood pressure during rapid changes in head and body position with respect to gravity.


Subject(s)
Baroreflex/radiation effects , Electric Stimulation/methods , Reflex, Vestibulo-Ocular/radiation effects , Sympathetic Nervous System/radiation effects , Vestibular Nerve/radiation effects , Adult , Baroreflex/physiology , Blood Pressure/physiology , Blood Pressure/radiation effects , Electrocardiography , Female , Heart Rate/radiation effects , Humans , Male , Reaction Time/radiation effects
11.
Circulation ; 108(6): 724-8, 2003 Aug 12.
Article in English | MEDLINE | ID: mdl-12885750

ABSTRACT

BACKGROUND: In patients with neurogenic orthostatic hypotension (NOH), the availability of the sympathetic neurotransmitter norepinephrine (NE) in the synaptic cleft is insufficient to maintain blood pressure while in the standing posture. METHODS AND RESULTS: We determined the effect of oral administration of the synthetic amino acid L-threo-3,4-dihydroxyphenylserine (L-DOPS), which is decarboxylated to NE by the enzyme L-aromatic amino acid decarboxylase (L-AADC) in neural and nonneural tissue, on blood pressure and orthostatic tolerance in 19 patients with severe NOH (8 with pure autonomic failure and 11 with multiple-system atrophy). A single-blind dose-titration study determined the most appropriate dose for each patient. Patients were then enrolled in a double-blind, placebo-controlled, crossover trial. L-DOPS significantly raised mean blood pressure both supine (from 101+/-4 to 141+/-5 mm Hg) and standing (from 60+/-4 to 100+/-6 mm Hg) for several hours and improved orthostatic tolerance in all patients. After L-DOPS, blood pressure increases were closely associated with increases in plasma NE levels. Oral administration of carbidopa, which inhibits L-AADC outside the blood-brain barrier, blunted both the increase in plasma NE and the pressor response to L-DOPS in all patients CONCLUSIONS: Acute administration of L-DOPS increases blood pressure and improves orthostatic tolerance in patients with NOH. The pressor effect results from conversion of L-DOPS to NE outside the central nervous system.


Subject(s)
Droxidopa/therapeutic use , Hypotension, Orthostatic/drug therapy , Norepinephrine/physiology , Administration, Oral , Aged , Antiparkinson Agents/adverse effects , Antiparkinson Agents/pharmacokinetics , Antiparkinson Agents/therapeutic use , Aromatic-L-Amino-Acid Decarboxylases/drug effects , Aromatic-L-Amino-Acid Decarboxylases/metabolism , Blood Pressure/drug effects , Carbidopa/pharmacology , Cross-Over Studies , Double-Blind Method , Droxidopa/adverse effects , Droxidopa/pharmacokinetics , Female , Hemodynamics/drug effects , Humans , Hypotension, Orthostatic/etiology , Hypotension, Orthostatic/physiopathology , Male , Middle Aged , Neurodegenerative Diseases/complications , Norepinephrine/biosynthesis , Norepinephrine/blood , Posture , Single-Blind Method , Treatment Outcome
12.
Ann Neurol ; 52(3): 342-5, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12205647

ABSTRACT

Neurally mediated syncope is the most frequent cause of syncope in patients without structural heart disease. Its most common trigger is a reduction in venous return to the heart due to excessive venous pooling in the legs. We conducted a double-blind, randomized, crossover trial to investigate the efficacy of midodrine, a selective alpha-1 adrenergic agonist that decreases venous capacitance, in preventing neurally mediated syncope triggered by passive head-up tilt. Twelve patients with history of recurrent neurally mediated syncope, which was reproduced during head-up tilt, were randomized to receive a nonpressor dose of midodrine (5mg) or placebo on day 1 and the opposite on day 3. One hour after drug or placebo administration, patients underwent 60-degree head-up tilt lasting 40 minutes (unless hypotension or bradycardia developed first). In the supine position, midodrine produced no significant change in blood pressure or heart rate. The responses to head-up tilt were significantly different on the midodrine and the placebo day: on the placebo day, 67% (8/12) of the subjects suffered neurally mediated syncope, whereas only 17% (2/12) of the subjects developed neurally mediated syncope on the midodrine day (p < 0.02). These results indicate that midodrine significantly improves orthostatic tolerance during head-up tilt in patients with recurrent neurally mediated syncope.


Subject(s)
Midodrine/therapeutic use , Syncope, Vasovagal/drug therapy , Vasoconstrictor Agents/therapeutic use , Adult , Blood Pressure/drug effects , Cross-Over Studies , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Hypotension, Orthostatic/drug therapy , Hypotension, Orthostatic/prevention & control , Male , Middle Aged , Syncope, Vasovagal/prevention & control , Tilt-Table Test
SELECTION OF CITATIONS
SEARCH DETAIL